Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CONy 2021 | The treatment of menstrually-related migraine & outstanding issues

Simona Sacco, MD, University of L’Aquila, L’Aquila, Italy, discusses the treatment of menstrually-related migraine. The treatment of acute migraine includes NSAID and triptan therapy; however, these treatments are not effective in all patients. On the other hand, preventative treatment seeks to reduce the frequency, severity and duration of migraine attacks. Such treatment primarily includes drug classes from other diseases such as antidepressants and antiepileptics; however, a new class of anti-CGRP therapies that includes monoclonal antibodies constitutes a potential disease-modifying treatment for migraine. Despite these recent advances, menstruation-related migraine attacks constitute an unmet clinical need. This highlights the necessity for more high-quality data regarding the efficacy of estrogen in migraine. This interview was conducted during the virtual 2021 World Congress on Controversies in Neurology (CONy) meeting.

Disclosures

Eli Lilly, Teva, Novartis, Allergan-Abbvie, Abbott, AstraZeneca, NovoNordisk.